Auris Medical Holding AG (NASDAQ:EARS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. “

Separately, Roth Capital reiterated a “buy” rating and issued a $5.00 target price on shares of Auris Medical Holding AG in a research note on Saturday, July 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Auris Medical Holding AG has a consensus rating of “Hold” and a consensus price target of $3.25.

Shares of Auris Medical Holding AG (EARS) traded down 3.8088% during midday trading on Wednesday, hitting $0.9117. 360,082 shares of the company were exchanged. The firm’s 50 day moving average price is $0.75 and its 200 day moving average price is $0.75. Auris Medical Holding AG has a one year low of $0.60 and a one year high of $1.50. The firm’s market capitalization is $40.41 million.

Auris Medical Holding AG (NASDAQ:EARS) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.09. Analysts forecast that Auris Medical Holding AG will post ($0.63) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/zacks-investment-research-downgrades-auris-medical-holding-ag-ears-to-hold.html.

A number of large investors have recently modified their holdings of the business. Virtu KCG Holdings LLC purchased a new stake in shares of Auris Medical Holding AG in the second quarter worth about $101,000. UBS Oconnor LLC purchased a new stake in shares of Auris Medical Holding AG in the first quarter worth about $909,000. Perceptive Advisors LLC purchased a new stake in shares of Auris Medical Holding AG in the first quarter worth about $368,000. Finally, Sabby Management LLC purchased a new stake in shares of Auris Medical Holding AG in the first quarter worth about $133,000. Hedge funds and other institutional investors own 28.38% of the company’s stock.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get a free copy of the Zacks research report on Auris Medical Holding AG (EARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.